Epigenetic profiles of response to transcranial magnetic stimulation in treatment resistant depression

Peripheral blood DNA methylation was profiled in 46 patients with treatment-resistant depression prior to treatment with transcranial magnetic stimulation (TMS). Genome-wide DNA methylation was measured using the Illumina Infinium MethylationEPIC BeadChip (850K array). Following quality control, data from 46 subjects were included in downstream analyses. Treatment outcomes were assessed using the PHQ-9 depression scale and included treatment response (≥50% reduction in PHQ-9), symptom trajectory (ΔPHQ-9), and remission (PHQ-9 score < 5). Methylation data were analyzed to identify differentially methylated regions (DMRs) associated with treatment outcomes. Both raw IDAT files and processed beta-value data are provided. Peripheral blood samples were collected and analyzed from 46 patients with treatment-resistant depression prior to a standardized 36-session course of transcranial magnetic stimulation (TMS) treatment. Genomic DNA was extracted and bisulfite converted for methylation profiling using the Illumina Infinium MethylationEPIC BeadChip (850K array). After sample-level quality control, 46 samples were retained for analysis. DNA methylation data were analyzed in relation to clinical outcomes based on PHQ-9 scores, including treatment response, symptom change, and remission status.